Tysabri Relatively Safe For Short-Term Use, NEJM Concludes
This article was originally published in The Pink Sheet Daily
Executive Summary
No further cases of PML found in two large trials, but editorial urges caution.
You may also be interested in...
“Lax” MS Trial Entry Criteria Is A Threat To Patient Safety, Lancet Article Says
Authors calls for safeguards against inclusion of misdiagnosed patients in MS trials.
“Lax” MS Trial Entry Criteria Is A Threat To Patient Safety, Lancet Article Says
Authors calls for safeguards against inclusion of misdiagnosed patients in MS trials.
UCB Cimzia BLA Submission Could Provide First Subcutaneous Injection For Crohn’s
Requested priority review could result in approval by early September for competitor to J&J’s Remicade and AstraZeneca’s Entocort EC.